RaySearch Laboratories (Schweden)
eröffnet am 21.05.19 14:18:24 von
neuester Beitrag 16.05.22 19:44:12 von
neuester Beitrag 16.05.22 19:44:12 von
Beiträge: 13
ID: 1.304.186
ID: 1.304.186
Aufrufe heute: 0
Gesamt: 1.447
Gesamt: 1.447
Aktive User: 0
ISIN: SE0000135485 · WKN: 905265
9,7850
EUR
-1,16 %
-0,1150 EUR
Letzter Kurs 19.04.24 Lang & Schwarz
Neuigkeiten
Werte aus der Branche Informationstechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 70,50 | +188,93 | |
| 0,6120 | +32,75 | |
| 3,2000 | +23,08 | |
| 1,1500 | +21,69 | |
| 4,1000 | +20,59 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,8000 | -37,78 | |
| 0,7500 | -40,00 | |
| 12,300 | -47,21 | |
| 7,0000 | -62,10 | |
| 82,75 | -68,36 |
Beitrag zu dieser Diskussion schreiben
Feedback
https://www.marketscreener.com/quote/stock/RAYSEARCH-LABORAT…
Leider meiner Depotbereinigung zum Opfer gefallen.
Leider meiner Depotbereinigung zum Opfer gefallen.
Tongji-Krankenhaus wählt RayStation
https://de.marketscreener.com/kurs/aktie/RAYSEARCH-LABORATOR…
Ein hoher Anspruch:
https://www.raysearchlabs.com/about-raysearch/
RaySearch Laboratories AB (publ) ist ein Medizintechnikunternehmen, das innovative Softwarelösungen für eine verbesserte Krebsbehandlung entwickelt. Wir sind ein engagierter Pionier. Unsere Systeme nutzen bahnbrechende Automatisierung und maschinelles Lernen, um neue Möglichkeiten für die Pflege zu schaffen und die Effizienz für unsere Kunden und Partner zu steigern. Und darauf arbeiten wir hin: eine Welt, in der der Krebs besiegt ist.
Die letzten Nachrichten:
https://de.marketscreener.com/kurs/aktie/RAYSEARCH-LABORATOR…
https://de.marketscreener.com/kurs/aktie/RAYSEARCH-LABORATOR…
https://de.marketscreener.com/kurs/aktie/RAYSEARCH-LABORATOR…
https://de.marketscreener.com/kurs/aktie/RAYSEARCH-LABORATOR…
https://www.raysearchlabs.com/about-raysearch/
RaySearch Laboratories AB (publ) ist ein Medizintechnikunternehmen, das innovative Softwarelösungen für eine verbesserte Krebsbehandlung entwickelt. Wir sind ein engagierter Pionier. Unsere Systeme nutzen bahnbrechende Automatisierung und maschinelles Lernen, um neue Möglichkeiten für die Pflege zu schaffen und die Effizienz für unsere Kunden und Partner zu steigern. Und darauf arbeiten wir hin: eine Welt, in der der Krebs besiegt ist.
Die letzten Nachrichten:
https://de.marketscreener.com/kurs/aktie/RAYSEARCH-LABORATOR…
https://de.marketscreener.com/kurs/aktie/RAYSEARCH-LABORATOR…
https://de.marketscreener.com/kurs/aktie/RAYSEARCH-LABORATOR…
https://de.marketscreener.com/kurs/aktie/RAYSEARCH-LABORATOR…
Die Wende nach Covid
Sehr tiefgehende Analysehttp://www.globalstockpicking.com/2022/03/13/raysearch-the-p…
" CFO erklärt, dass sie die Forschung und Entwicklung von diesem Niveau aus auch nicht weiter ausbauen werden, sodass der Nettogewinn und der Cashflow in Zukunft besser auf eine stabilere Ausgabenbasis für Forschung und Entwicklung ausgerichtet sein sollten."
"Das Bärenszenario ist meines Erachtens unwahrscheinlich, es geht im Grunde von einem Totalausfall bei der Steigerung zukünftiger Umsätze aus. Dies würde bedeuten, dass die gesamte F&E und die Verdopplung des Personals teilweise verlorene Investitionen gewesen wären (oder Investitionen, die nur getätigt wurden, um mit der Konkurrenz Schritt zu halten). Das Basisszenario verfolgt einen konservativen Turnaround-Ansatz. Der Umsatz wird wachsen, aber mit einer moderaten Rate, was noch wichtiger ist, die Betriebsmargen werden sich nur langsam erholen und nie vollständig auf das Niveau von 2016-2017 zurückkehren. Das Bullenszenario sieht 4-5 Jahre mit sehr starkem Umsatzwachstum vor, das sich später als im Jahresvergleich verlangsamt, mehr in Richtung der von der Industrie prognostizierten Wachstumsniveaus. Die Betriebsmarge erholt sich auch viel schneller und erreicht höhere Niveaus, wenn das Unternehmen in seinem Betrieb Skaleneffekte erzielt."
"Dies gibt mir ein gewichtetes Kursziel von 85 SEK , was ungefähr 85 % über dem zuletzt gehandelten Kurs liegt."
Weiß irgendjemand irgendwas krinr news garnichts nichts los
Trading Spotlight
Eher gegen süden
Was ist denn hier los? Warum explodieren wir gerade hier gerade gen Norden? Any news?
Die aktie ist unterbewertet
RaySearch releases preliminary results for the third quarter 2019
PDF
RaySearch Laboratories AB (publ) releases preliminary figures for the third quarter of 2019. The order intake is expected to increase by 12 percent to SEK 197 (176) million. Net sales for the third quarter of 2019 are expected to amount to
SEK 144 (150) million and the operating profit is expected to amount to SEK -6 (12) million. The operating profit was affected by positive currency translation effects and adjusted for this, the operating profit had declined to SEK -26 M (18). Cash flow for the period amounts to SEK -13 (-17) million.
The lower operating profit during the quarter is mainly due to two factors:
Weaker license sales in the US and Europe – RaySearch is a growth company where individual, large orders can have significant effects on revenue recognition between the quarters.
Increased operating costs – as a result of the company’s expansion, the number of employees has increased by 22 percent over the past 12 months, mainly within the global market organization and in research and development. In addition, the ASTRO trade fair was held in the third quarter of 2019 compared with the fourth quarter of the previous year, and total depreciation has increased by 60 percent, mainly as a result of the company's investments in new offices, but also due to the application of IFRS 16.
“We are accustomed to the fact that large orders can affect the revenue recognition between the quarters. After a record first half-year, sales were weaker in the third quarter. However, the market situation and the demand for our products are still good and we feel secure with our strategy”, says Johan Löf, CEO of RaySearch Laboratories AB.
The above figures are preliminary and a full year-end report for the period January to September 2019 will be released on November 14, 2019 at 07.45 CET as previously announced.
RaySearch Laboratories AB (publ) releases preliminary figures for the third quarter of 2019. The order intake is expected to increase by 12 percent to SEK 197 (176) million. Net sales for the third quarter of 2019 are expected to amount to
SEK 144 (150) million and the operating profit is expected to amount to SEK -6 (12) million. The operating profit was affected by positive currency translation effects and adjusted for this, the operating profit had declined to SEK -26 M (18). Cash flow for the period amounts to SEK -13 (-17) million.
The lower operating profit during the quarter is mainly due to two factors:
Weaker license sales in the US and Europe – RaySearch is a growth company where individual, large orders can have significant effects on revenue recognition between the quarters.
Increased operating costs – as a result of the company’s expansion, the number of employees has increased by 22 percent over the past 12 months, mainly within the global market organization and in research and development. In addition, the ASTRO trade fair was held in the third quarter of 2019 compared with the fourth quarter of the previous year, and total depreciation has increased by 60 percent, mainly as a result of the company's investments in new offices, but also due to the application of IFRS 16.
“We are accustomed to the fact that large orders can affect the revenue recognition between the quarters. After a record first half-year, sales were weaker in the third quarter. However, the market situation and the demand for our products are still good and we feel secure with our strategy”, says Johan Löf, CEO of RaySearch Laboratories AB.
The above figures are preliminary and a full year-end report for the period January to September 2019 will be released on November 14, 2019 at 07.45 CET as previously announced.
HJ zahlen, passt.
“In the second quarter, order intake rose 80 percent and net sales grew 34 percent.
Cash flow before financing activities increased to SEK 80 M (-49)”
SECOND QUARTER (APRIL-JUNE 2019)
Net sales SEK 189.7 M (141.0),
Profit after tax SEK 21.8 M (20.6) and earnings per share before/after dilution SEK 0.64 (0.60)
Operating profit SEK 28.8 M (26.2)
Cash flow SEK 4.1 M (-50.3)
Order intake SEK 370.6 M (206.2),
Order backlog SEK 1,043.1 M (723.5) at the end of the period
HALF-YEAR (JANUARY-JUNE 2019)
Net sales SEK 362.7 M (257.3)
Profit after tax SEK 39.0 M (32.4) and earnings per share before/after dilution SEK 1.14 (0.94)
Operating profit SEK 52.0 M (40.4)
Cash flow SEK 2.3 M (-37.9)
Order intake SEK 572.2 M (334.6)
SIGNIFICANT EVENTS DURING THE SECOND QUARTER
The RayStation® treatment planning system was chosen by several leading cancer centers, including Moffitt Cancer Center and Loma Linda University Medical Center in the US, Genolier Clinic (part of the Swiss Medical Network) in Switzerland, AKH Vienna/Medical University of Vienna in Austria and Proton Therapy Center Czech in the Czech Republic.
RaySearch and Mevion Medical Systems extended their strategic collaboration to further advance capabilities of HYPERSCAN treatment planning.
RaySearch received orders from MedAustron GmbH for the RayCare® oncology information system and the RayCommand® treatment control system, representing the single largest combined order valued to date in the company’s history.
The RayCare oncology information system was also chosen by Genolier Clinic (part of the Swiss Medical Network).
RayStation 9A*, the latest version of RaySearch’s treatment planning system, was released in June.
RaySearch also received FDA clearance for RayStation 8B, which includes the first machine learning applications in a treatment planning system on the market.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
RayCare 3A*, the latest version of RaySearch’s oncology information system, was released in July.
RaySearch and Vision RT announced a strategic development partnership.
“In the second quarter, order intake rose 80 percent and net sales grew 34 percent.
Cash flow before financing activities increased to SEK 80 M (-49)”
SECOND QUARTER (APRIL-JUNE 2019)
Net sales SEK 189.7 M (141.0),
Profit after tax SEK 21.8 M (20.6) and earnings per share before/after dilution SEK 0.64 (0.60)
Operating profit SEK 28.8 M (26.2)
Cash flow SEK 4.1 M (-50.3)
Order intake SEK 370.6 M (206.2),
Order backlog SEK 1,043.1 M (723.5) at the end of the period
HALF-YEAR (JANUARY-JUNE 2019)
Net sales SEK 362.7 M (257.3)
Profit after tax SEK 39.0 M (32.4) and earnings per share before/after dilution SEK 1.14 (0.94)
Operating profit SEK 52.0 M (40.4)
Cash flow SEK 2.3 M (-37.9)
Order intake SEK 572.2 M (334.6)
SIGNIFICANT EVENTS DURING THE SECOND QUARTER
The RayStation® treatment planning system was chosen by several leading cancer centers, including Moffitt Cancer Center and Loma Linda University Medical Center in the US, Genolier Clinic (part of the Swiss Medical Network) in Switzerland, AKH Vienna/Medical University of Vienna in Austria and Proton Therapy Center Czech in the Czech Republic.
RaySearch and Mevion Medical Systems extended their strategic collaboration to further advance capabilities of HYPERSCAN treatment planning.
RaySearch received orders from MedAustron GmbH for the RayCare® oncology information system and the RayCommand® treatment control system, representing the single largest combined order valued to date in the company’s history.
The RayCare oncology information system was also chosen by Genolier Clinic (part of the Swiss Medical Network).
RayStation 9A*, the latest version of RaySearch’s treatment planning system, was released in June.
RaySearch also received FDA clearance for RayStation 8B, which includes the first machine learning applications in a treatment planning system on the market.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
RayCare 3A*, the latest version of RaySearch’s oncology information system, was released in July.
RaySearch and Vision RT announced a strategic development partnership.
Durchsuchen
